Study identifier:D1531C00007
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A phase I/II, open label, multi-centre study to assess the safety, tolerability, pharmacokinetics and efficacy of AZD1152 in patients with acute myeloid leukaemia.
Myeloid Leukemia
Phase 1
No
AZD1152
All
65
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to assess safety and tolerability of multiple ascending doses of AZD1152 and to assess effect of AZD1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia.
Location
Location
ANGERS CEDEX, France
Location
GRENOBLE CEDEX, France
Location
LE CHESNAY CEDEX, France
Location
BOLOGNA, Italy
Location
ROMA, Italy
Location
AMSTERDAM, Netherlands
Location
NIJMEGEN, Netherlands
Location
ROTTERDAM, Netherlands
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.